학술논문

Corrigendum: Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
Document Type
article
Source
Frontiers in Oncology, Vol 13 (2024)
Subject
endometrial cancer
molecular classification
immune checkpoint inhibitors
dostarlimab
pembrolizumab plus lenvatinib
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Language
English
ISSN
2234-943X